1 week ago
Aptus Pharma Plans Rs 45 Crore Raise and Expansion
Aptus Pharma wants to collect Rs 45 crore to grow its business.
The plan must first be approved by shareholders and regulators.
The company says it may use the money over 36 months after receiving it.
It wants to make some of its products in its own factories.
Its goal is to produce about 20 per cent of its needs itself.
This could help the company manage quality, supplies and product availability.
Aptus Pharma also wants to sell its products in more parts of India.
It is considering business opportunities in Africa, the Middle East and Latin America.
These overseas plans will depend on market conditions, regulations and whether they make commercial sense.
Aptus Pharma plans to raise Rs 45 crore through a preferential issue.
The fundraising requires shareholder approval at the Annual General Meeting on September 14, 2026, along with other regulatory clearances.
The company aims to eventually manufacture about 20 per cent of its product requirements in-house.
Aptus Pharma plans to expand its domestic sales and distribution network toward a Pan-India presence.
The company is exploring opportunities in Africa, the Middle East and Latin America through registrations, exports and partnerships.
- Who
- Aptus Pharma.
- What
- Aptus Pharma plans to raise Rs 45 crore, increase in-house manufacturing and expand its domestic and international operations.
- Where
- The company plans to expand across West, Central, East and South India and explore Africa, the Middle East and Latin America.
- When
- The shareholder vote is scheduled for September 14, 2026; proceeds are proposed to be used within 36 months of receipt.
- Why
- To strengthen manufacturing, quality control, supply-chain management, product availability, brand development and market expansion.
Key facts
- Planned fundraising
- Rs 45 crore through a preferential issue
- Shareholder approval
- Annual General Meeting scheduled for September 14, 2026
- Use of proceeds
- Proposed to be utilised within 36 months of receiving the funds
- Manufacturing target
- Eventually meet around 20 per cent of product requirements through in-house manufacturing
- Domestic expansion
- Strengthen sales and distribution across West, Central, East and South India
- International markets
- Africa, the Middle East and Latin America
- Expansion conditions
- Commercial viability, market conditions and regulatory approvals
Sources
Related news
Natco Pharma Expands Beyond Generics Amid Intensifying Competition
Amrutanjan Health targets 1 lakh direct chemist outlets in FY27
India’s Manufacturing Majors Scale Capacity Across Strategic Industries
Biodeal Pharmaceuticals Raises ₹385 Crore From RMB Capitalworks For Expansion And R&D
Entero and Medplus Target India’s Expanding Pharmacy Market
Shanti Inorganics Plans ₹47 Crore IPO on NSE Emerge
USS Abraham Lincoln Docks in Thailand
Gold Prices Fall Further Amid US-Iran Tensions and Rate Fears
Iran Says It Targeted US Forces in Bahrain
Gold falls to two-week low as yields, dollar pressure prices
Jefferies Sees 33% Reliance Industries Upside Amid Refinery Disruptions
